Opdivo

我们是谁

  • 2022 年 4 月 5 日
    Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
  • 2022 年 4 月 5 日
    Nivolumab 和 Ipilimumab 以及放疗治疗 MSS 和 MSI 高的结直肠癌和胰腺癌
  • 2022 年 4 月 5 日
    Ipilimumab, Maraviroc and Nivolumab (LUMINESCENCE)
  • 2022 年 4 月 5 日
    Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
  • 2022 年 4 月 5 日
    METIMMOX: Colorectal Cancer METastasis – Shaping Anti-tumor IMMunity by OXaliplatin
  • 2022 年 4 月 5 日
    Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
  • 2022 年 4 月 5 日
    Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer